Mertect lsp
Brand names,
Mertect lsp
Analogs
Mertect lsp
Brand Names Mixture
Mertect lsp
Chemical_Formula
C11H16N2O
Mertect lsp
RX_link
http://www.rxlist.com/cgi/generic3/tocainide.htm
Mertect lsp
fda sheet
Mertect lsp
msds (material safety sheet)
Mertect lsp
Synthesis Reference
No information avaliable
Mertect lsp
Molecular Weight
192.258 g/mol
Mertect lsp
Melting Point
246-266 oC
Mertect lsp
H2O Solubility
1.07E+004 mg/L
Mertect lsp
State
Solid
Mertect lsp
LogP
1.308
Mertect lsp
Dosage Forms
400 mg and 600 mg tablets for oral administration
Mertect lsp
Indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
Mertect lsp
Pharmacology
Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.
Mertect lsp
Absorption
Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
Mertect lsp
side effects and Toxicity
The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
Mertect lsp
Patient Information
Mertect lsp
Organisms Affected
Humans and other mammals